Show cover of The Lancet Haematology in conversation with

The Lancet Haematology in conversation with

Lan-Lan Smith, Editor-in-Chief, and Emma Cookson, Senior Editor at The Lancet Haematology, in conversation with the journal’s authors, explore their latest research and its impact on people’s health, healthcare, and health policy.A monthly audio companion to the journal, this podcast covers a broad range of topics, from racial and ethnic disparities in leukaemia survival outcomes to resuscitation with blood products compared with saline, the link between mental health and lymphoma to haemolytic disease in newborns, and more.

Tracks

Banu Aygun on sickle cell anaemia
Professor Banu Aygun joins us to discuss the REACH trial testing hydroxyurea dose optimisation for children with sickle cell anaemia in sub-Saharan Africa.Read the full article:https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(24)00078-4?dgcid=buzzsprout_icw_podcast_generic_lanhaeContinue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv
11:13 5/23/24
Sabine Braat and Katherine Fielding on haemoglobin thresholds to define anaemia
Dr Sabine Braat and Dr Katherine Fielding join us to discuss their study presenting new haemoglobin thresholds for defining anaemia.Read the full article:https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(24)00030-9/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanhaeContinue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv
18:06 3/1/24
Elisabeth Schorb on the MARTA phase 2 trial
Doctor Elisabeth Schorb joins us to discuss the MARTA phase 2 trial, treating older, fit patients with primary diffuse large B-cell CNS lymphoma with high-dose chemotherapy and autologous stem-cell transplantation.Read the full article:https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(23)00371-X/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanhaeContinue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv
09:23 2/29/24
Stephan Ehl on paediatric autoimmune lymphoproliferative immunodeficiencies
Professor Stephan Ehl joins us to discuss a prospective observational study on paediatric autoimmune lymphoproliferative immunodeficiencies.Read the full article:https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00638-1/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanoncContinue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv
13:03 1/31/24
Dr Sarah O'Brien on the PREVAPIX-ALL trial
Dr Sarah O'Brien joins Lan-Lan Smith to discuss results of the phase 3 PREVAPIX-ALL trial, which compares direct oral anticoagulant apixaban to low-molecular-weight-heparin for the prevention of venous thromboembolism in children with newly diagnosed acute lymphoblastic leukaemia or lymphoma.Read the full article:https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(23)00314-9/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanhaeContinue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv
13:50 12/20/23
Enrico Lopriore on haemolytic disease of the fetus and newborn
Professor Enrico Lopriore joins us to discuss a trial testing darbepoetin alfa to prevent postnatal anaemia in infants with haemolytic disease of the fetus and newborn.Read the full article:https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(23)00285-5/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanhaeContinue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv
12:33 11/29/23
Meletios Dimopoulos on relapsed and refractory multiple myeloma
Professor Meletios Dimopoulos joins us to discuss two trials for patients with relapsed and refractory multiple myeloma - the first report of the DREAMM-3 phase 3 and long-term follow-up of the APOLLO phase 3 trial.Read the full article:https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(23)00243-0/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanhaeContinue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv
11:00 10/3/23
Eric Ohuma on haemoglobin concentrations and neonatal outcomes
Dr Eric Ohuma joins us to tell us about a study recently published in The Lancet Haematology on the association between maternal haemoglobin concentrations and maternal and neonatal outcomes.Read the full article:https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(23)00170-9/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanhaeContinue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv
16:27 8/29/23
Margaret Ragni on tranexamic acid to treat heavy menstrual bleeding
Professor Margaret Ragni joins us to discuss the VWDMin study, published in The Lancet Haematology. In this phase 3, randomised, crossover trial, recombinant von Willebrand factor and tranexamic acid are used to treat heavy menstrual bleeding in patients with mild and moderate von Willebrand disease in the USA. Read the full article:https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(23)00119-9/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanhaeContinue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv
13:13 7/31/23
Oreofe Odejide and Thomas Kuczmarski on mental health and lymphoma
Dr Odejide and Dr Kuczmarski tell us about a study recently published in The Lancet Haematology on the effect of pre-existing mental health conditions on survival in patients with diffuse large B-cell lymphoma.Read the full article:https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(23)00094-7/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanhaeContinue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv
16:32 7/3/23
Alok Srivastava on fitusiran for patients with haemophilia A and B
Professor Alok Srivastava tells us about two clinical trials being published in The Lancet and The Lancet Haematology on a new siRNA therapy called fitusiran for patients with haemophilia A and B.Read the two trials:Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH)https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)00284-2/fulltext?dgcid=buzzsprout_icw_podcast_buzzsprout_generalFitusiran prophylaxis in people with severe haemophilia A or haemophilia B without inhibitors (ATLAS-A/B)https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(23)00037-6/fulltext?dgcid=buzzsprout_icw_podcast_buzzsprout_generalContinue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv
18:41 3/29/23
Emmanuela E Ambrose on stroke prevention in children with sickle cell disease
Dr Emmanuela E Ambrose tells us about the SPHERE trial on hydroxyurea dose escalation for primary stroke prevention in children with sickle cell disease in TanzaniaRead the full article:Hydroxyurea with dose escalation for primary stroke risk reduction in children with sickle cell anaemia in Tanzania (SPHERE)Continue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv
11:31 3/2/23
Sumit Gupta on racial and ethnic disparities in leukaemia survival outcomes
Dr Sumit Gupta discusses how racial and ethnic disparities affect survival outcomes of children and young adults with acute lymphocytic leukaemia.Read the full article:Racial and ethnic disparities in childhood and young adult acute lymphocytic leukaemiaContinue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv
22:10 1/30/23
Xiao-Jun Huang on cellular therapy in China
Professor Xiao-Jun Huang discusses this Lancet Haematology series on Cellular Therapy in China, covering the history, current research challenges, and future of HSCT and CAR T-cell therapies in China.Read the Series papers:Cellular therapy in ChinaContinue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv
28:10 11/28/22
Glenn Pierce on haemophilia care in LMICs
Dr Glenn Pierce discusses the World Federation of Hemophilia’s Humanitarian Aid Program which provides access to haemophilia care in low-income and lower-middle-income countries.Read the full Review:Achieving access to haemophilia care in low-income and lower-middle-income countriesContinue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv
34:55 8/30/22
Amy DeZern on the link between myelodysplastic syndrome and autoimmune disorders
Dr Amy DeZern discusses the link between myelodysplastic syndrome and autoimmune disorders and the need for a multidisciplinary approach for the treatment of patients who have both.Read the full article:Myelodysplastic syndrome and autoimmune disorders: two sides of the same coin?Continue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv
12:50 6/30/22
Nicholas Crombie and Gavin Perkins on resuscitation with blood products compared with saline
Dr Nicholas Crombie and Professor Gavin Perkins discuss their randomised phase 3 trial in which they investigated resuscitation with blood products compared with saline in patients with trauma-related haemorrhagic shock receiving prehospital care. Continue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv
15:05 3/7/22
Fredrik Schjesvold on OCEAN phase 3
Dr Fredrik Schjesvold discusses the results of the OCEAN phase 3 trial testing melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide. Read the full article:Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN)Continue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv
12:24 1/31/22
Jacob D Soumerai and Andrew D Zelenetz on the BOVen regimen for previously untreated patients with chronic lymphocytic leukaemia
Dr Jacob D Soumerai and Prof Andrew D Zelenetz discuss their phase 2 trial of the BOVen regimen and MRD-driven treatment discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma.Read the full article:https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(21)00307-0/fulltext Continue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv
11:59 11/25/21
Raul Cordoba on haematological malignancies in older people
Dr Raul Cordoba discusses the joint Series between The Lancet Healthy Longevity and The Lancet Haematology on haematological malignancies in older people.Read the full article:A comprehensive approach to therapy of haematological malignancies in older patientsContinue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv
16:24 11/3/21
Obiageli Nnodu and Dennis Chao on child mortality from sickle cell disease in Nigeria
Professor Obiageli Nnodu and Dr Dennis Chao join acting Deputy Editor Emma Cookson to talk about their new study describing modelling of child mortality as a result of sickle cell disease in Nigeria. Read the full article:https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(21)00191-5/fulltextContinue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv
09:03 9/21/21
Zuguo Mei and Gary Brittenham on iron deficiency
Senior Assistant Editor Ben Burwood speaks with Dr Zuguo Mei (Division of Nutrition, Physical Activity, and Obesity, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, GA, USA)  and Dr Gary M Brittenham (Department of Pediatrics, College of Physicians and Surgeons, Columbia University, New York, NY, USA) about their work defining physiologically based serum ferritin thresholds for iron deficiency.Read the full article:https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(21)00168-X/fulltextContinue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv
08:34 7/27/21
Eugenia Trigoso Arjona (in Spanish) on nursing and haematological care
Para el Día International de la Enfermera, Eugenia Trigoso Arjona, enfermera coordinadora en el Hospital La Fe (Valencia, España) y presidenta del comité de educación de la European Society for Blood and Marrow Transplantation Nurses hablo con la Editora Yaiza del Pozo Martin sobre como las enfermeras pueden remodelar el futuro de la hematología. Continue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv
29:11 5/11/21
Eugenia Trigoso Arjona (in English) on nursing and haematological care
To mark International Nurses Day, Eugenia Trigoso Arjona, nurse coordinator at Hospital La Fe (Valencia, Spain) and chair of the European Society for Blood and Marrow Transplantation Nurses Global Education Committee, joins acting Editor-in-Chief Yaiza del Pozo Martin to discuss how nurses can reshape the future of haematological care. Continue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv
28:34 5/11/21
Nada Hamad on inclusion and diversity in haematology
A/Prof Nada Hamad (St Vincent’s hospital, Sydney, Australia) joins Editor-in-Chief Dr Lan-Lan Smith to discuss inclusion and diversity in haematology-oncology and transplantation.  Continue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv
30:02 2/23/21
Dr Judith Boer on lymphoblastic leukaemia in children
Editor-in-Chief, Dr Lan-Lan Smith, speaks with Dr Judith Boer (Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands) about outcome of ABL-class acute lymphoblastic leukaemia in children in the pre-tyrosine kinase inhibitor era.Read the full article:https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(20)30353-7/fulltextContinue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv
10:24 12/22/20
Imatinib for paediatric leukaemia
Andrea Biondi joins The Lancet Haematology to discuss his work on imatinib as a treatment for paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia.Continue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv
08:33 12/15/18
Predicting the risk of adenoviraemia
Prashant Hiwarkar joins The Lancet Haematology to discuss his new paper, an investigation into whether serial faecal PCR monitoring can predict the risk of adenoviraemia and survival outcomes after HSCT.Continue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv
04:51 8/31/18
Adverse events in haematological malignancies
Lead author Gita Thanarajasingam joins The Lancet Haematology to discuss the new Commission on assessment and adverse event reporting in haematological malignancies.Continue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv
12:31 6/12/18
EPO blood doping and cycling: The Lancet Haematology: June 29, 2017
Jules Heuberger talks about his study on the effectiveness of EPO use by cyclists.Continue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv
08:34 6/30/17